PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis

Bone microenvironment and cell-cell interactions are crucial for the initiation and development of metastasis. By means of a pharmacologic approach, using the multitargeted tyrosine kinase inhibitor sunitinib, we tested the relevance of the platelet-derived growth factor receptor (PDGFR) axis in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2011, Vol.71 (1), p.164-174
Hauptverfasser: CATENA, Raúl, LUIS-RAVELO, Diego, ANTON, Iker, ZANDUETA, Carolina, SALAZAR-COLOCHO, Pablo, LARZABAL, Leyre, CALVO, Alfonso, LECANDA, Fernando
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 174
container_issue 1
container_start_page 164
container_title Cancer research (Chicago, Ill.)
container_volume 71
creator CATENA, Raúl
LUIS-RAVELO, Diego
ANTON, Iker
ZANDUETA, Carolina
SALAZAR-COLOCHO, Pablo
LARZABAL, Leyre
CALVO, Alfonso
LECANDA, Fernando
description Bone microenvironment and cell-cell interactions are crucial for the initiation and development of metastasis. By means of a pharmacologic approach, using the multitargeted tyrosine kinase inhibitor sunitinib, we tested the relevance of the platelet-derived growth factor receptor (PDGFR) axis in the bone marrow (BM) stromal compartment for the initiation and development of lung cancer metastasis to bone. PDGFRβ was found to be the main tyrosine kinase target of sunitinib expressed in BM stromal ST-2 and MC3T3-E1 preosteoblastic cells. In contrast, no expression of sunitinib-targeted receptors was found in A549M1 and low levels in H460M5 lung cancer metastatic cells. Incubation of ST-2 and human BM endothelial cells with sunitinib led to potent cell growth inhibition and induction of apoptosis in a dose-dependent manner. Similarly, sunitinib induced a robust proapoptotic effect in vivo on BM stromal PDGFRβ(+) cells and produced extensive disruption of tissue architecture and vessel leakage in the BM cavity. Pretreatment of ST-2 cells with sunitinib also hindered heterotypic adhesion to lung cancer cell lines. These effects were correlated with changes in cell-cell and cell-matrix molecules in both stromal and tumor cells. Pretreatment of mice with sunitinib before intracardiac inoculation of A549M1 or H460M5 cells caused marked inhibition of tumor cells homing to bone, whereas no effect was found when tumor cells were pretreated before inoculation. Treatment with sunitinib dramatically increased overall survival and prevented tumor colonization but not bone lesions, whereas combination with zoledronic acid resulted in marked reduction of osteolytic lesions and osseous tumor burden. Thus, disruption of the PDGFR axis in the BM stroma alters heterotypic tumor-stromal and tumor-matrix interactions, thereby preventing efficient engagement required for bone homing and osseous colonization. These results support the notion that concomitant targeting of the tumor and stromal compartment is a more effective approach for blocking bone metastasis.
doi_str_mv 10.1158/0008-5472.CAN-10-1708
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954618013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>822555569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-15f987d603a6023225ab5b7df2df1d9aa61df3def667756316b95d75602697b63</originalsourceid><addsrcrecordid>eNqFkF1PwjAUhhujEUR_gqY3xqthz7q22yWgIAmoEb1eurUl031gu8X47y2CeulJk9M2z3tO8iB0DmQIwOJrQkgcsEiEw8noPgASgCDxAeoDo3Egoogdov4v00Mnzr36JwPCjlEvBJIIAUkfLR9vZtMnvCrWtSyLeo3HZZO_SaVxUeOltLb5wKvWNpXE82ojC-vwovPYRNa5tnjc1BovdSudP4U7RUdGlk6f7fsAvUxvnyd3weJhNp-MFkEegWgDYCaJheKESk5CGoZMZiwTyoTKgEqk5KAMVdpwLgTjFHiWMOVvJOSJyDgdoKvd3I1t3jvt2rQqXK7LUta66VyasIhDTID-S8Z-uS-eeJLtyNw2zllt0o0tKmk_UyDpVnm61ZludaZe-fevV-5zF_sNXVZp9Zv6ceyByz0gXS5LY726wv1xVAAPuaBfzeuHBA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>822555569</pqid></control><display><type>article</type><title>PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>CATENA, Raúl ; LUIS-RAVELO, Diego ; ANTON, Iker ; ZANDUETA, Carolina ; SALAZAR-COLOCHO, Pablo ; LARZABAL, Leyre ; CALVO, Alfonso ; LECANDA, Fernando</creator><creatorcontrib>CATENA, Raúl ; LUIS-RAVELO, Diego ; ANTON, Iker ; ZANDUETA, Carolina ; SALAZAR-COLOCHO, Pablo ; LARZABAL, Leyre ; CALVO, Alfonso ; LECANDA, Fernando</creatorcontrib><description>Bone microenvironment and cell-cell interactions are crucial for the initiation and development of metastasis. By means of a pharmacologic approach, using the multitargeted tyrosine kinase inhibitor sunitinib, we tested the relevance of the platelet-derived growth factor receptor (PDGFR) axis in the bone marrow (BM) stromal compartment for the initiation and development of lung cancer metastasis to bone. PDGFRβ was found to be the main tyrosine kinase target of sunitinib expressed in BM stromal ST-2 and MC3T3-E1 preosteoblastic cells. In contrast, no expression of sunitinib-targeted receptors was found in A549M1 and low levels in H460M5 lung cancer metastatic cells. Incubation of ST-2 and human BM endothelial cells with sunitinib led to potent cell growth inhibition and induction of apoptosis in a dose-dependent manner. Similarly, sunitinib induced a robust proapoptotic effect in vivo on BM stromal PDGFRβ(+) cells and produced extensive disruption of tissue architecture and vessel leakage in the BM cavity. Pretreatment of ST-2 cells with sunitinib also hindered heterotypic adhesion to lung cancer cell lines. These effects were correlated with changes in cell-cell and cell-matrix molecules in both stromal and tumor cells. Pretreatment of mice with sunitinib before intracardiac inoculation of A549M1 or H460M5 cells caused marked inhibition of tumor cells homing to bone, whereas no effect was found when tumor cells were pretreated before inoculation. Treatment with sunitinib dramatically increased overall survival and prevented tumor colonization but not bone lesions, whereas combination with zoledronic acid resulted in marked reduction of osteolytic lesions and osseous tumor burden. Thus, disruption of the PDGFR axis in the BM stroma alters heterotypic tumor-stromal and tumor-matrix interactions, thereby preventing efficient engagement required for bone homing and osseous colonization. These results support the notion that concomitant targeting of the tumor and stromal compartment is a more effective approach for blocking bone metastasis.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.CAN-10-1708</identifier><identifier>PMID: 21097719</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Angiogenesis Inhibitors - pharmacology ; Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Bone Marrow Cells - drug effects ; Bone Marrow Cells - metabolism ; Bone Neoplasms - prevention &amp; control ; Bone Neoplasms - secondary ; Cell Adhesion - drug effects ; Cell Line ; Cell Proliferation - drug effects ; Diseases of the osteoarticular system ; Gene Expression Profiling ; Humans ; Indoles - pharmacology ; Lung Neoplasms - pathology ; Medical sciences ; Mice ; Neoplasm Invasiveness ; Pharmacology. Drug treatments ; Pneumology ; Pyrroles - pharmacology ; Receptors, Platelet-Derived Growth Factor - antagonists &amp; inhibitors ; Receptors, Platelet-Derived Growth Factor - metabolism ; Signal Transduction ; Stromal Cells - drug effects ; Stromal Cells - metabolism ; Tumors ; Tumors of striated muscle and skeleton ; Tumors of the respiratory system and mediastinum</subject><ispartof>Cancer research (Chicago, Ill.), 2011, Vol.71 (1), p.164-174</ispartof><rights>2015 INIST-CNRS</rights><rights>2010 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-15f987d603a6023225ab5b7df2df1d9aa61df3def667756316b95d75602697b63</citedby><cites>FETCH-LOGICAL-c417t-15f987d603a6023225ab5b7df2df1d9aa61df3def667756316b95d75602697b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23716267$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21097719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CATENA, Raúl</creatorcontrib><creatorcontrib>LUIS-RAVELO, Diego</creatorcontrib><creatorcontrib>ANTON, Iker</creatorcontrib><creatorcontrib>ZANDUETA, Carolina</creatorcontrib><creatorcontrib>SALAZAR-COLOCHO, Pablo</creatorcontrib><creatorcontrib>LARZABAL, Leyre</creatorcontrib><creatorcontrib>CALVO, Alfonso</creatorcontrib><creatorcontrib>LECANDA, Fernando</creatorcontrib><title>PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Bone microenvironment and cell-cell interactions are crucial for the initiation and development of metastasis. By means of a pharmacologic approach, using the multitargeted tyrosine kinase inhibitor sunitinib, we tested the relevance of the platelet-derived growth factor receptor (PDGFR) axis in the bone marrow (BM) stromal compartment for the initiation and development of lung cancer metastasis to bone. PDGFRβ was found to be the main tyrosine kinase target of sunitinib expressed in BM stromal ST-2 and MC3T3-E1 preosteoblastic cells. In contrast, no expression of sunitinib-targeted receptors was found in A549M1 and low levels in H460M5 lung cancer metastatic cells. Incubation of ST-2 and human BM endothelial cells with sunitinib led to potent cell growth inhibition and induction of apoptosis in a dose-dependent manner. Similarly, sunitinib induced a robust proapoptotic effect in vivo on BM stromal PDGFRβ(+) cells and produced extensive disruption of tissue architecture and vessel leakage in the BM cavity. Pretreatment of ST-2 cells with sunitinib also hindered heterotypic adhesion to lung cancer cell lines. These effects were correlated with changes in cell-cell and cell-matrix molecules in both stromal and tumor cells. Pretreatment of mice with sunitinib before intracardiac inoculation of A549M1 or H460M5 cells caused marked inhibition of tumor cells homing to bone, whereas no effect was found when tumor cells were pretreated before inoculation. Treatment with sunitinib dramatically increased overall survival and prevented tumor colonization but not bone lesions, whereas combination with zoledronic acid resulted in marked reduction of osteolytic lesions and osseous tumor burden. Thus, disruption of the PDGFR axis in the BM stroma alters heterotypic tumor-stromal and tumor-matrix interactions, thereby preventing efficient engagement required for bone homing and osseous colonization. These results support the notion that concomitant targeting of the tumor and stromal compartment is a more effective approach for blocking bone metastasis.</description><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Cells - drug effects</subject><subject>Bone Marrow Cells - metabolism</subject><subject>Bone Neoplasms - prevention &amp; control</subject><subject>Bone Neoplasms - secondary</subject><subject>Cell Adhesion - drug effects</subject><subject>Cell Line</subject><subject>Cell Proliferation - drug effects</subject><subject>Diseases of the osteoarticular system</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Lung Neoplasms - pathology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Neoplasm Invasiveness</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Pyrroles - pharmacology</subject><subject>Receptors, Platelet-Derived Growth Factor - antagonists &amp; inhibitors</subject><subject>Receptors, Platelet-Derived Growth Factor - metabolism</subject><subject>Signal Transduction</subject><subject>Stromal Cells - drug effects</subject><subject>Stromal Cells - metabolism</subject><subject>Tumors</subject><subject>Tumors of striated muscle and skeleton</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1PwjAUhhujEUR_gqY3xqthz7q22yWgIAmoEb1eurUl031gu8X47y2CeulJk9M2z3tO8iB0DmQIwOJrQkgcsEiEw8noPgASgCDxAeoDo3Egoogdov4v00Mnzr36JwPCjlEvBJIIAUkfLR9vZtMnvCrWtSyLeo3HZZO_SaVxUeOltLb5wKvWNpXE82ojC-vwovPYRNa5tnjc1BovdSudP4U7RUdGlk6f7fsAvUxvnyd3weJhNp-MFkEegWgDYCaJheKESk5CGoZMZiwTyoTKgEqk5KAMVdpwLgTjFHiWMOVvJOSJyDgdoKvd3I1t3jvt2rQqXK7LUta66VyasIhDTID-S8Z-uS-eeJLtyNw2zllt0o0tKmk_UyDpVnm61ZludaZe-fevV-5zF_sNXVZp9Zv6ceyByz0gXS5LY726wv1xVAAPuaBfzeuHBA</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>CATENA, Raúl</creator><creator>LUIS-RAVELO, Diego</creator><creator>ANTON, Iker</creator><creator>ZANDUETA, Carolina</creator><creator>SALAZAR-COLOCHO, Pablo</creator><creator>LARZABAL, Leyre</creator><creator>CALVO, Alfonso</creator><creator>LECANDA, Fernando</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QP</scope></search><sort><creationdate>2011</creationdate><title>PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis</title><author>CATENA, Raúl ; LUIS-RAVELO, Diego ; ANTON, Iker ; ZANDUETA, Carolina ; SALAZAR-COLOCHO, Pablo ; LARZABAL, Leyre ; CALVO, Alfonso ; LECANDA, Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-15f987d603a6023225ab5b7df2df1d9aa61df3def667756316b95d75602697b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Cells - drug effects</topic><topic>Bone Marrow Cells - metabolism</topic><topic>Bone Neoplasms - prevention &amp; control</topic><topic>Bone Neoplasms - secondary</topic><topic>Cell Adhesion - drug effects</topic><topic>Cell Line</topic><topic>Cell Proliferation - drug effects</topic><topic>Diseases of the osteoarticular system</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Lung Neoplasms - pathology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Neoplasm Invasiveness</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Pyrroles - pharmacology</topic><topic>Receptors, Platelet-Derived Growth Factor - antagonists &amp; inhibitors</topic><topic>Receptors, Platelet-Derived Growth Factor - metabolism</topic><topic>Signal Transduction</topic><topic>Stromal Cells - drug effects</topic><topic>Stromal Cells - metabolism</topic><topic>Tumors</topic><topic>Tumors of striated muscle and skeleton</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CATENA, Raúl</creatorcontrib><creatorcontrib>LUIS-RAVELO, Diego</creatorcontrib><creatorcontrib>ANTON, Iker</creatorcontrib><creatorcontrib>ZANDUETA, Carolina</creatorcontrib><creatorcontrib>SALAZAR-COLOCHO, Pablo</creatorcontrib><creatorcontrib>LARZABAL, Leyre</creatorcontrib><creatorcontrib>CALVO, Alfonso</creatorcontrib><creatorcontrib>LECANDA, Fernando</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CATENA, Raúl</au><au>LUIS-RAVELO, Diego</au><au>ANTON, Iker</au><au>ZANDUETA, Carolina</au><au>SALAZAR-COLOCHO, Pablo</au><au>LARZABAL, Leyre</au><au>CALVO, Alfonso</au><au>LECANDA, Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2011</date><risdate>2011</risdate><volume>71</volume><issue>1</issue><spage>164</spage><epage>174</epage><pages>164-174</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Bone microenvironment and cell-cell interactions are crucial for the initiation and development of metastasis. By means of a pharmacologic approach, using the multitargeted tyrosine kinase inhibitor sunitinib, we tested the relevance of the platelet-derived growth factor receptor (PDGFR) axis in the bone marrow (BM) stromal compartment for the initiation and development of lung cancer metastasis to bone. PDGFRβ was found to be the main tyrosine kinase target of sunitinib expressed in BM stromal ST-2 and MC3T3-E1 preosteoblastic cells. In contrast, no expression of sunitinib-targeted receptors was found in A549M1 and low levels in H460M5 lung cancer metastatic cells. Incubation of ST-2 and human BM endothelial cells with sunitinib led to potent cell growth inhibition and induction of apoptosis in a dose-dependent manner. Similarly, sunitinib induced a robust proapoptotic effect in vivo on BM stromal PDGFRβ(+) cells and produced extensive disruption of tissue architecture and vessel leakage in the BM cavity. Pretreatment of ST-2 cells with sunitinib also hindered heterotypic adhesion to lung cancer cell lines. These effects were correlated with changes in cell-cell and cell-matrix molecules in both stromal and tumor cells. Pretreatment of mice with sunitinib before intracardiac inoculation of A549M1 or H460M5 cells caused marked inhibition of tumor cells homing to bone, whereas no effect was found when tumor cells were pretreated before inoculation. Treatment with sunitinib dramatically increased overall survival and prevented tumor colonization but not bone lesions, whereas combination with zoledronic acid resulted in marked reduction of osteolytic lesions and osseous tumor burden. Thus, disruption of the PDGFR axis in the BM stroma alters heterotypic tumor-stromal and tumor-matrix interactions, thereby preventing efficient engagement required for bone homing and osseous colonization. These results support the notion that concomitant targeting of the tumor and stromal compartment is a more effective approach for blocking bone metastasis.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>21097719</pmid><doi>10.1158/0008-5472.CAN-10-1708</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2011, Vol.71 (1), p.164-174
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_954618013
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Angiogenesis Inhibitors - pharmacology
Animals
Antineoplastic agents
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Biological and medical sciences
Bone Marrow Cells - drug effects
Bone Marrow Cells - metabolism
Bone Neoplasms - prevention & control
Bone Neoplasms - secondary
Cell Adhesion - drug effects
Cell Line
Cell Proliferation - drug effects
Diseases of the osteoarticular system
Gene Expression Profiling
Humans
Indoles - pharmacology
Lung Neoplasms - pathology
Medical sciences
Mice
Neoplasm Invasiveness
Pharmacology. Drug treatments
Pneumology
Pyrroles - pharmacology
Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors
Receptors, Platelet-Derived Growth Factor - metabolism
Signal Transduction
Stromal Cells - drug effects
Stromal Cells - metabolism
Tumors
Tumors of striated muscle and skeleton
Tumors of the respiratory system and mediastinum
title PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A00%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PDGFR%20Signaling%20Blockade%20in%20Marrow%20Stroma%20Impairs%20Lung%20Cancer%20Bone%20Metastasis&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=CATENA,%20Ra%C3%BAl&rft.date=2011&rft.volume=71&rft.issue=1&rft.spage=164&rft.epage=174&rft.pages=164-174&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/10.1158/0008-5472.CAN-10-1708&rft_dat=%3Cproquest_cross%3E822555569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=822555569&rft_id=info:pmid/21097719&rfr_iscdi=true